Economic Evaluation of First-Line Atezolizumab for Extensive-Stage Small-Cell Lung Cancer in the US

• 主要な著者: Yingcheng Wang (著者), Mingjun Rui (著者), Lan Yang (著者), Xintian Wang (著者), Ye Shang (著者), Aixia Ma (著者), Hongchao Li (著者)
• フォーマット: 図書
• 出版事項: Frontiers Media S.A., 2021-04-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Introduction: This study evaluated the cost-effectiveness of atezolizumab + chemotherapy vs. chemotherapy as first-line treatment for extensive-stage small-cell lung cancer (SCLC) in the United States (US).Methods: The three health states partitioned survival (PS) model was used over the lifetime. E...